Conventional versus Doxorubicin-Eluting Beads Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma: a Tertiary Medical Centre Experience in Malaysia |
Rahman, F Abdul
(Gastroenterology Unit, Department of Medicine, Universiti Sains Islam Malaysia)
Naidu, J (Gastroenterology Unit, Department of Medicine, Universiti Sains Islam Malaysia) Ngiu, CS (Gastroenterology Unit, Department of Medicine, Universiti Sains Islam Malaysia) Yaakob, Y (Endovascular and Interventional Unit, Department of Radiology, Universiti Sains Islam Malaysia) Mohamed, Z (Endovascular and Interventional Unit, Department of Radiology, Universiti Sains Islam Malaysia) Othman, H (Hepatobiliary Unit, Department of Surgery, Universiti Sains Islam Malaysia) Jarmin, R (Hepatobiliary Unit, Department of Surgery, Universiti Sains Islam Malaysia) Elias, MH (Department of Physiology, Faculty of Medicine, Universiti Kebangsaan Malaysia Medical Centre, Universiti Sains Islam Malaysia) Hamid, N Abdul (Department of Physiology, Faculty of Medicine, Universiti Kebangsaan Malaysia Medical Centre, Universiti Sains Islam Malaysia) Mokhtar, N Mohd (Department of Physiology, Faculty of Medicine, Universiti Kebangsaan Malaysia Medical Centre, Universiti Sains Islam Malaysia) Ali, RA Raja (Gastroenterology Unit, Department of Medicine, Universiti Sains Islam Malaysia) |
1 | Meza-Junco J, Montano-Loza AJ, Liu DM, et al (2012). Locoregional radiological treatment for hepatocellular carcinoma; Which, when and how? Cancer Treat Rev, 38, 54-62. DOI |
2 | Pascual S, Herrera I, Irurzun J (2016). New advances in hepatocellular carcinoma. World J Hepatol, 8, 421-38. DOI |
3 | Au JS, Frenette CT (2015). Management of Hepatocellular Carcinoma: Current Status and Future Directions. Gut Liver, 9, 437-48 DOI |
4 | Torre LA, Bray F, Siegel RL, et al (2015). Global cancer statistics, 2012. CA Cancer J Clin, 65, 87-108. DOI |
5 | Schultheiss M, Bettinger D, Neeff HP, et al (2015). Hepatocellular Carcinoma: therapeutic options 2015. Dtsch Med Wochenschr, 140, 1063-8. DOI |
6 | Sherman M (2010). Epidemiology of hepatocellular carcinoma. Oncol, 78, 7-10. DOI |
7 | Song MJ, Park CH, Kim JD, et al (2011). Drug-eluting bead loaded with doxorubicin versus conventional Lipiodolbased transarterial chemoembolization in the treatment of hepatocellular carcinoma: a case-control study of Asian patients. Eur J Gastroenterol Hepatol, 23, 521-7. DOI |
8 | Vincenzi B, Di Maio M, Silletta M, et al (2015). Prognostic Relevance of Objective Response According to EASL Criteria and mRECIST Criteria in Hepatocellular Carcinoma Patients Treated with Loco-Regional Therapies: A Literature- Based Meta-Analysis. PLoS One, 10, 133488. |
9 | Yang XD, Pan LH, Wang L, et al (2015). Systematic review of single large and/or multinodular hepatocellular carcinoma: surgical resection improves survival. Asian Pac J Cancer Prev, 16, 5541-7 DOI |
10 | Wang DY, Liu L, Qi XS, et al (2015). Hepatic re-resection versus transarterial chemoembolization for the treatment of recurrent hepatocellular carcinoma after initial resection: a systematic review and meta-analysis. Asian Pac J Cancer Prev, 16, 5573-8. DOI |
11 | Zu QQ, Liu S, Zhou CG, et al (2015). Chemoembolization of recurrent hepatoma after curative resection: prognostic factors. Am J Roentgenol, 204, 1322-8. DOI |
12 | Sasaki Y (2015). Progress of Regional Therapy for Hepatocellular Carcinoma. Gan To Kagaku Ryoho, 42, 771-7. |
13 | Chen KW, Ou TM, Hsu CW, et al (2015). Current systemic treatment of hepatocellular carcinoma: A review of the literature. World J Hepatol, 7, 1412-20 DOI |
14 | Arabi M, BenMousa A, Bzeizi K, et al (2015). Doxorubicinloaded drug-eluting beads versus conventional transarterial chemoembolization for nonresectable hepatocellular carcinoma. Saudi J Gastroenterol, 21, 175-80 DOI |
15 | Borzio M, Dionigi E, Parisi G, et al (2015). Management of hepatocellular carcinoma in the elderly. World J Hepatol, 7, 1521-9 DOI |
16 | Boulin M, Delhom E, Pierredon-Foulongne MA, et al (2015). Transarterial chemoembolization for hepatocellular carcinoma: An old method, now flavor of the day. Diagn Interv Imaging, 96, 607-15. DOI |
17 | Brown DB, Geschwind JF, Soulen MC, et al (2006). Society of Interventional Radiology position statement on chemoembolization of hepatic malignancies. J Vasc Interv Radiol, 17, 217-23 DOI |
18 | Bruix J, Sherman M, Llovet JM, et al (2001). Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol, 35, 421-30. DOI |
19 | Ciria R, Lopez-Cillero P, Gallardo AB, et al (2015). Optimizing the management of patients with BCLC stage-B hepatocellular carcinoma: Modern surgical resection as a feasible alternative to transarterial chemoemolization. Eur J Surg Oncol, 41, 1153-61 DOI |
20 | Di Costanzo GG, Tortora R (2015). Intermediate hepatocellular carcinoma: How to choose the best treatment modality? World J Hepatol, 7, 1184-91. DOI |
21 | El-Serag HB (2012). Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterol, 142, 1264-73. DOI |
22 | Kawahara D, Ozawa S, Hioki K, et al (2015). SU-D-BRB-07: Lipiodol Impact On Dose Distribution in Liver SBRT After TACE. Med Phys, 42, 3212. |
23 | Lammer J, Malagari K, Vogl T, et al (2010). Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study. Cardiovasc Intervent Radiol, 33, 41-52. DOI |
24 | Kudo M (2015). Surveillance, diagnosis, treatment, and outcome of liver cancer in Japan. Liver Cancer, 4, 39-50. DOI |
25 | Kew MC (2010). Epidemiology of chronic hepatitis B virus infection, hepatocellular carcinoma, and hepatitis B virusinduced hepatocellular carcinoma. Pathol Biol (Paris), 58, 273-7 DOI |
26 | Lafaro KJ, Demirjian AN, Pawlik TM (2015). Epidemiology of hepatocellular carcinoma. Surg Oncol Clin N Am, 24, 1-17. DOI |
27 | Lencioni R, de Baere T, Burrel M, et al (2012). Transcatheter treatment of hepatocellular carcinoma with Doxorubicinloaded DC Bead (DEBDOX): technical recommendations. Cardiovasc Intervent Radiol, 35, 980-5. DOI |
28 | Lencioni R, Llovet JM (2010). Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis, 30, 52-60. DOI |
29 | Lo CM, Ngan H, Tso WK, et al (2002). Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatol, 35, 1164-71. DOI |
30 | Llovet JM, Real MI, Montana X, et al (2002). Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet, 359, 1734-9. DOI |